Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security, and global markets, today announced the award of the Short/Medium Range Sub-Orbital ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, ...

PBFT02 is a gene therapy that utilizes an AAV1 viral vector to deliver, through ICM administration ... improved lysosomal function and reduced neuroinflammation. Passage Bio (Nasdaq: PASG) is a ...

Transaction Details Pacira intends to maintain GQ Bio’s operations and invest in its HCAd gene therapy vector platform and innovative products built on the platform, leveraging Pacira’s clinical, ...

So-Young (SY) announced that Nasdaq approved the company’s request to transfer the listing of the company’s American depositary shares, with every 13 ADSs representing 10 Class A ordinary ...

Chijet Motor (CJET) announced that, on February 13, 2025, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ...

Kratos and RAFAEL (through its U.S. based subsidiary RAFAEL USA) have jointly committed up to $175 million in capital for the establishment of Prometheus and required property, plant, equipment and ...

It was not so long ago that entertainment giant Paramount (PARA) faced a serious dilemma. It could fight back against a lawsuit coming in from the President of the United States, Donald Trump, or ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...